CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • PRPH Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit

ProPhase Labs (PRPH) News and press releases

Company Profile

News

From Benzinga Pro
A Look Into Healthcare Sector Value Stocks
23 Jan 23
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
11 Jan 23
Movers
5 Value Stocks In The Healthcare Sector
9 Jan 23
News
ProPhase Labs's Return On Capital Employed Overview
20 Dec 22
Earnings
ProPhase Labs Acquires Rights To Novel Esophageal Cancer Test For ~$4.5M
19 Dec 22
Biotech, M&A, General
ProPhase Labs, Inc. "ProPhase" (NASDAQ:PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it has entered into an asset purchase agreement to acquire
5 Value Stocks In The Healthcare Sector
5 Dec 22
News
HC Wainwright & Co. Maintains Buy on ProPhase Labs, Raises Price Target to $15
11 Nov 22
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Yi Chen maintains ProPhase Labs (NASDAQ:PRPH) with a Buy and raises the price target from $14 to $15.
ProPhase Labs Q3 EPS $0.06 Misses $0.19 Estimate, Sales $24.20M Beat $21.42M Estimate
10 Nov 22
Earnings, News
ProPhase Labs (NASDAQ:PRPH) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.19 by 68.42 percent. This is a 123.08 percent increase over losses of $(0.26) per share from
Earnings Scheduled For November 10, 2022
10 Nov 22
Earnings
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter.
ProPhase Labs Announces Collaboration With Dana-Farber Cancer Institute
8 Nov 22
News
ProPhase Labs, Inc. (NASDAQ:PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly owned subsidiary, ProPhase BioPharma, Inc. (“PBIO”), and

Press releases

From Benzinga Pro
ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test
19 Dec 22
Press Releases
GARDEN CITY, NY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. "ProPhase" (NASDAQ:PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it has entered into an
ProPhase Labs to Present at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022
30 Nov 22
Press Releases
GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be presenting at the
ProPhase Labs Announces Record Third Quarter 2022 Financial Results
10 Nov 22
Press Releases
Q3 2022 Net Revenues of $24.2 Million (a Q3 record); Up 155% Year-over-Year Q3 2022 Net Income of $1.0 Million versus a loss in Q3 2021 Q3 2022 adjusted EBITDA of $6.3 million (a Q3 record) versus a loss in
ProPhase Labs to Present at Investor Summit Group's Q4 Conference
7 Nov 22
Press Releases
GARDEN CITY, NY, Nov. 07, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be participating in the Q4
Finsight
Resources
  • Knowledgebase
  • Log In
  • Register
Company
  • About
  • Contact
  • Solutions
Products
  • Deal Roadshow
  • DealVDR
  • Evercall
  • Finsight.com
CapEdge
  • Earnings Calendar
  • Earnings Transcripts
  • EDGAR Filing Screener
  • IPO Calendar
  • Compliance
  • Privacy
  • Security
  • Terms
AngelList LinkedIn